The Newswire for Business Lawyers

Biovail Fires Back At AstraZeneca In Seroquel IP Suit

Law360, New York (April 06, 2009) -- Biovail Corp. has become the latest generics maker to ask a court to invalidate or rule unenforceable two patents for Seroquel XR — AstraZeneca Pharmaceuticals LP's popular treatment for bipolar disorder and schizophrenia — filing counterclaims that accuse the pharmaceutical giant of inequitable conduct.

The counterclaims, filed Friday in the U.S. District Court for the District of New Jersey, argue that one of the patents is unenforceable because the patent applicants failed to share...

Login

E-mail
Password
 
  I forgot my login details.

For the whole story, take a 7-day free trial.

Submit your request to try Law360 for free for seven days:

*
*
*
*
*
*
*
*

*Required

Select at least one interest area:*
You will receive Law360's free daily newsletter for the interest area(s) selected..

Appellate
Bankruptcy
Competition
Contract
Corporate Finance
Employment
Energy
Environmental
Financial Services
Health
Insurance
Intellectual Property
International Trade
Product Liability
Securities
Technology
Top News (General Interest)
The only daily news service covering every major practice area of the law.
  • Breaking news available nowhere else
  • More than 66% of articles published before or simultaneously with any other source
  • 44% of articles have critical legal documents attached
  • More than 1,000 columns by leading practitioners published per year
  • More than 20,000 exclusive articles published per year
  • Detailed coverage of 16 major practice areas